Safety and efficacy of 3 DMARDs for 2 years of treatment in patients with early rheumatoid arthritis

Trial Profile

Safety and efficacy of 3 DMARDs for 2 years of treatment in patients with early rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2015

At a glance

  • Drugs Bucillamine (Primary) ; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TRED
  • Most Recent Events

    • 07 Feb 2015 According to UMIN, the date for data entry closure is 31 Aug 2013, and the date for conclusion of data analysis is 31 Dec 2013.
    • 18 Jul 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 07 Jan 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top